


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:56Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406940" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406940</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjophth</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open Ophthalmol</journal-id><journal-id journal-id-type="pmc-domain-id">3334</journal-id><journal-id journal-id-type="pmc-domain">bmjophth</journal-id><journal-id journal-id-type="publisher-id">bmjophth</journal-id><journal-title-group><journal-title>BMJ Open Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2397-3269</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406940</article-id><article-id pub-id-type="pmcid-ver">PMC12406940.1</article-id><article-id pub-id-type="pmcaid">12406940</article-id><article-id pub-id-type="pmcaiid">12406940</article-id><article-id pub-id-type="pmid">40889896</article-id><article-id pub-id-type="doi">10.1136/bmjophth-2025-002226</article-id><article-id pub-id-type="publisher-id">bmjophth-2025-002226</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Orbit and Oculoplastics</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>2356</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Mitigating the risks: addressing smoking cessation in thyroid eye disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2045-6163</contrib-id><name name-style="western"><surname>Karimi</surname><given-names initials="N">Nasser</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0347-5549</contrib-id><name name-style="western"><surname>Kashkouli</surname><given-names initials="MB">Mohsen Bahmani</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-6684-8720</contrib-id><name name-style="western"><surname>Keyhani</surname><given-names initials="A">Ali</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3333-8425</contrib-id><name name-style="western"><surname>Aghili</surname><given-names initials="S">SeyyedSaeed</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6498-1408</contrib-id><name name-style="western"><surname>Ghahvehchian</surname><given-names initials="H">Hossein</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2617-0975</contrib-id><name name-style="western"><surname>Askari</surname><given-names initials="S">Sahar</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-2623-3034</contrib-id><name name-style="western"><surname>Akbarian</surname><given-names initials="S">Shadi</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label>1</label><institution content-type="department">Eye Research Center, Department of Ophthalmology, The Five Senses Health Institute, Moheb Kowsar Hospital, School of Medicine</institution>, <institution specific-use="Ringgold_440827">Iran University of Medical Sciences</institution>, <city>Tehran</city>, <country>Iran (the Islamic Republic of)</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Ophthalmology and Visual Sciences</institution>, <institution specific-use="Ringgold_12254">University of Louisville School of Medicine</institution>, <city>Louisville</city>, <state>Kentucky</state>, <country>USA</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Physiology, School of Medicine</institution>, <institution specific-use="Ringgold_440827">Iran University of Medical Sciences</institution>, <city>Tehran</city>, <country>Iran (the Islamic Republic of)</country></aff></contrib-group><author-notes><corresp id="cor1">Dr Shadi Akbarian; <email xlink:href="akbarianshadi@gmail.com">akbarianshadi@gmail.com</email></corresp><fn fn-type="COI-statement" id="fn3"><p>None declared.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2025</year></pub-date><volume>10</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">480211</issue-id><elocation-id>e002226</elocation-id><history><date date-type="received"><day>17</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjophth-10-1.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjophth-10-1.pdf"/><abstract><title>Abstract</title><sec><title>Objective</title><p>This study aimed to assess the effectiveness of verbal counselling and varenicline in achieving smoking cessation among patients with thyroid eye disease (TED) and to identify predictive factors associated with successful smoking cessation.</p></sec><sec><title>Methods and analysis</title><p>A cross-sectional analysis of data from the Iran TED (IrTED) Registry was conducted. Patients&#8217; demographics and TED severity/activity were recorded. As a routine at the TED clinic in Rassoul Akram Hospital, since 2020, all smoking patients have undergone smoking cessation verbal counselling in the first and almost every subsequent visit session. The effectiveness of verbal counselling was assessed through a telephone survey. Retrospectively, the association between successful smoking cessation and disease severity/activity was evaluated. Prospectively, patients who failed or refused to quit smoking after counselling were offered varenicline. Acceptance, compliance and adherence rates were determined.</p></sec><sec><title>Results</title><p>While 379/685 patients of the IrTED 2013&#8211;2023 database (55.32%) reported no tobacco exposure, the remaining were active (n=117, 17.08%), passive (n=134, 19.56%) and former smokers (n=55, 8.02%). In 2020&#8211;2023, 73 active tobacco-smoking patients with TED were enrolled, all of whom received verbal cessation counselling at their first and subsequent visits. On the follow-up phone call, 51/73 were contacted, and 25/51 (49.01%) reported successful smoking cessation after verbal counselling. The remaining 26/51 smokers were offered varenicline (on the phone call); however, only 7/26 (26.92%) attended the prescription session. Of these patients, 3/7 (42.85%) completed the first month of treatment, and just 1/3 (33.33%) finished the 3-month course, successfully quitting smoking until the final follow-up (18 months). One patient (14.28%) reported constipation, and another one reported sleep paralysis (14.28%) as an adverse event.</p></sec><sec><title>Conclusion</title><p>Verbal counselling demonstrates effectiveness in smoking cessation for patients with TED, with nearly half of smokers successfully quitting the habit. Among those who failed to quit after verbal counselling, varenicline showed limited effectiveness, indicating poor compliance and motivation deficit.</p></sec></abstract><kwd-group><kwd>Orbit</kwd><kwd>Ocular surface</kwd><kwd>Prospective Studies</kwd><kwd>Treatment Expectations</kwd><kwd>Eye (Globe)</kwd><kwd>Epidemiology</kwd><kwd>Eye Lids</kwd><kwd>Public health</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><sec><title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title><list list-type="bullet" list-content="ul"><list-item><p>While smoking is known to exacerbate thyroid eye disease (TED) progression and hinder treatment, data on the efficacy of verbal counselling and varenicline for smoking cessation within the TED population remains limited.</p></list-item></list></sec><sec><title>WHAT THIS STUDY ADDS</title><list list-type="bullet" list-content="ul"><list-item><p>Verbal counselling effectively promotes smoking cessation in patients with TED, with almost half successfully quitting. For those who continued smoking after counselling, varenicline had limited effectiveness, suggesting poor compliance and motivation issues.</p></list-item></list></sec><sec><title>HOW MIGHT THIS STUDY AFFECT RESEARCH, PRACTICE OR POLICY</title><list list-type="bullet" list-content="ul"><list-item><p>Consistent, evidence-based verbal counselling is likely sufficient and highly effective for patients with TED willing to quit smoking, with varenicline offering only minimal additional benefits.</p></list-item></list></sec></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Thyroid eye disease (TED) is an autoimmune-related ocular condition that can result in functional disabilities, such as restricted eye movement or compressive optic neuropathy, and cosmetic concerns due to lid abnormalities and exophthalmos.<xref rid="R1" ref-type="bibr"><sup>1 2</sup></xref> TED is most commonly observed in patients with Graves&#8217; hyperthyroidism, with a prevalence ranging from 25% to 40% in this population.<xref rid="R3" ref-type="bibr"><sup>3 4</sup></xref> Although TED typically occurs in a hyperthyroid state, it has also been reported in hypothyroid and euthyroid states.<xref rid="R5" ref-type="bibr">5</xref><xref rid="R7" ref-type="bibr">7</xref> The gender ratio for TED prevalence is approximately 2:1, indicating that the disease occurs about twice as frequently in women. However, this gender disparity tends to decrease with age, while disease severity increases.<xref rid="R8" ref-type="bibr"><sup>8 9</sup></xref></p><p>Cigarette smoking is widely recognised as the most significant modifiable risk factor for the onset and progression of TED.<xref rid="R10" ref-type="bibr"><sup>10 11</sup></xref> The incidence of TED is notably higher among patients with Graves&#8217; disease who smoke compared with non-smokers.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> A dose-dependent relationship between smoking and TED severity has been demonstrated.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> Moreover, smokers tend to exhibit weaker and delayed treatment responses.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p><p>Smoking cessation is beneficial in managing TED across multiple levels of prevention. At the primary prevention level, it aids in eliminating the key risk factor for TED onset; at the secondary level, it helps treat patients with mild or no complications; and at the tertiary level, it reduces disease-related disability.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Furthermore, smoking cessation has been found to effectively reverse the epigenetic changes caused by smoking, resulting in reduced incidence and severity of TED.<xref rid="R16" ref-type="bibr"><sup>16 17</sup></xref> A prospective study on patients with Graves&#8217; hyperthyroidism found that those who quit smoking at least a year before developing hyperthyroidism (ie, former smokers) had no increased risk of proptosis or diplopia compared with never-smokers.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> These findings reinforce the importance of smoking cessation in mitigating the risk of TED onset and progression.</p><p>Although limited research exists regarding smoking cessation interventions specifically for patients with TED, the available studies have yielded mixed results. On the one hand, a study conducted by Palomero <italic toggle="yes">et al</italic> found that oral counselling led to a cessation rate of 42.4% and a reduction in smoking for an additional 30.3% of patients.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> In contrast, another study reported that oral and behavioural interventions were not effective in smoking cessation among patients with TED.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> These conflicting findings underscore the need for further research on smoking cessation in TED patients.</p><p>Several pharmacological interventions are available for smoking cessation, including nicotine replacement therapies (eg, patches, chewing gums and tablets) as well as medications such as varenicline, bupropion and nortriptyline. Notably, varenicline and bupropion have received Food and Drug Administration approval for this indication. Among these options, varenicline has demonstrated efficacy in reducing the number of smoked cigarettes, craving and dependence,<xref rid="R20" ref-type="bibr">20</xref><xref rid="R23" ref-type="bibr">23</xref> leading to its recommendation as the first-line treatment for smoking cessation.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref></p><p>The primary objective of this study was to evaluate the effectiveness of verbal counselling and varenicline in facilitating smoking cessation among patients diagnosed with TED. Additionally, the study sought to identify factors that could predict successful smoking cessation among the studied patient group.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and methods</title><p>Using data from the Iran TED (IrTED) Registry (<ext-link xlink:href="https://orc.iums.ac.ir" ext-link-type="uri">https://orc.iums.ac.ir</ext-link>), this study examined patients who presented at Rassoul Akram Hospital&#8217;s oculoplastic clinic in Tehran, Iran, between March 2020 and March 2023.<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> The study complied with HIPAA and the Declaration of Helsinki.</p><p>As part of the standard care at the TED clinic in Rassoul Akram Hospital, since 2020, all smoking patients have received verbal counselling in the first and almost every subsequent visit session. The first author shared two evidence-based key points with the patients and answered their relevant questions:</p><list list-type="bullet" list-content="ul"><list-item><p>Smoking increases the incidence of proptosis by approximately twofold and triples the incidence of diplopia in patients with TED.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></p></list-item><list-item><p>Response to treatment is delayed and considerably poorer in patients with TED who smoke.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p></list-item></list><p>These two messages for the counselling were chosen partially based on a previous study on determinants of quality of life in Iranian patients with TED.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref></p><p>The study commenced by extracting the smoking status of all registered patients (2013&#8211;2023) at their initial visit (non-smoker, former smoker, passive smoker or current smoker) from the registry.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> Patients who smoked more than five cigarettes per week were classified as smokers. Active smokers at the first visit were selected for a follow-up telephone call to ascertain whether they had stopped or continued smoking after receiving the smoking cessation counselling (2020&#8211;2023) in the first visit. This self-reported information classified the smokers into two groups: persistent smoking and successful quitting. The inclusion criteria for the retrospective phase of the study comprised patients from both groups who had attended at least one subsequent clinical visit at least 3 months after their initial visit. During this phase of the study, the two groups were compared based on their <italic toggle="yes">baseline</italic> values and <italic toggle="yes">changes</italic> (from the first verbal counselling visit to the second clinical visit) in clinical indices to identify predictive factors associated with successful smoking cessation following verbal counselling. In the prospective phase of the study, patients who stated (on the follow-up phone call) that they refused or failed to quit smoking after verbal counselling were offered varenicline treatment. If they accepted, a clinical visit would be scheduled to provide them with the prescription and instructions for drug administration. A 3-month regimen of varenicline (0.5&#8201;mg per day for 3&#8201;days then 0.5&#8201;mg BD for 4&#8201;days then 1&#8201;mg BD for the rest of the regimen) was prescribed. Compliance and side effects of varenicline were recorded. Contraindications of starting varenicline included age under 18, pregnancy or breastfeeding.</p><p>TED Activity was defined as a CAS (clinical activity score) of or more equal to three. The severity of TED was scored following the EUGOGO (European Group on Graves' Orbitopathy) and NOSPECS system: (N) no signs and symptoms, (O) only signs, (S) soft tissue involvement, (P) proptosis, (E) extraocular muscle involvement, (C) corneal involvement and (S) sight loss.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref></p><p>The registration administrator (SAk) managed data collection, data cleaning and registry procedures to ensure adherence to quality standards throughout the study. Logistic regression analysis was applied to estimate the probability of adverse outcomes, such as active TED or sight-threatening TED. Sex variable was controlled as a potential confounding variable. For comparisons of quantitative (non-normally distributed) variables between groups, the Mann-Whitney U test was used. Categorical variables were analysed with dual tests of &#946; Pearson &#967;&#178; asymptotic significance (as a measure of association for <italic toggle="yes">nominal</italic> categorical variables) and &#947; Gamma approximate significance (as a measure of association for <italic toggle="yes">ordinal</italic> categorical variables) to examine the strength and direction of associations. All statistical analyses were performed using IBM SPSS Statistics V.25.</p><p>The current observational study adheres to the RECORD (Reporting of Studies Conducted Using Observational Routinely Collected Data) checklist to ensure comprehensive data reporting. Additionally, patients and the public were not involved in any aspect of the design, conduct, reporting or dissemination plans of the research.</p></sec><sec sec-type="results" id="s3"><title>Results</title><p>The IrTED database (2013&#8211;2023) included 685 patients (66.56%&#8201;women), with a mean age of 37.79 years (SD: 14.06, range 2&#8211;78). While 379 patients (55.32%) reported no tobacco exposure, the remaining were classified as active (n=117, 17.08%), passive (n=134, 19.56%) or former smokers (n=55, 8.02%). Significantly, active smoking rates differed between genders, with women at 7.24% and men at 36.68% (p&lt;0.01). <xref rid="F1" ref-type="fig">Figure 1</xref> illustrates the severity distribution of patients in the data pool based on smoking status at the initial visit. Although univariate analysis suggests active smoking may be linked to increased activity and severity in TED in the first visit, after adjusting for the confounding variable of gender, smoking status was not found to be associated with disease activity and severity (<xref rid="T1" ref-type="table">table 1</xref>).</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Distribution of severity profile of patients by smoking status at the first visit.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjophth-10-1-g001.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Correlation between smoking status and TED severity and activity at initial visit</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th colspan="6" valign="bottom" rowspan="1">OR (95%&#8201;CI) p value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1">Active TED<break/>(vs inactive TED)</td><td colspan="2" align="left" valign="top" rowspan="1">Sight-threatening TED<break/>(vs non-sight threatening)</td><td colspan="2" align="left" valign="top" rowspan="1">Sight-threatening or moderate&#8211;severe TED<break/>(vs mild TED)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Comparison</td><td align="left" valign="top" rowspan="1" colspan="1">Univariate analysis</td><td align="left" valign="top" rowspan="1" colspan="1">Adjusted for sex</td><td align="left" valign="top" rowspan="1" colspan="1">Univariate analysis</td><td align="left" valign="top" rowspan="1" colspan="1">Adjusted for sex</td><td align="left" valign="top" rowspan="1" colspan="1">Univariate analysis</td><td align="left" valign="top" rowspan="1" colspan="1">Adjusted for sex</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Current smoker versus passive smoker</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 3.66<break/>(2.04 to 6.59)<break/>p&lt;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.83<break/>(0.88 to 3.80)<break/>p: 0.10</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 21.06<break/>(2.75 to 161.51)<break/>p&lt;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 5.66<break/>(0.63 to 50.97)<break/>p: 0.12</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 2.25<break/>(1.33 to 3.82)<break/>p&lt;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.29<break/>(0.67 to 2.49)<break/>p: 0.44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Current smoker versus non-smoker</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 2.47<break/>(1.61 to 3.80)<break/>p&lt;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.37<break/>(0.85 to 2.21)<break/>p: 0.19</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 3.27<break/>(1.64 to 6.55)<break/>p&lt;0.01</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.67<break/>(0.80 to 3.49)<break/>p: 0.17</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.56<break/>(0.99 to 2.44)<break/>p: 0.05</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.28<break/>(0.77 to 2.15)<break/>p: 0.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Passive smoker versus non-smoker</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.48<break/>(0.89 to 2.47)<break/>p: 0.13</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.07<break/>(0.63 to 1.85)<break/>p: 0.78</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 6.42<break/>(0.85 to 48.33)<break/>p: 0.07</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 3.88<break/>(0.50 to 30.01)<break/>p: 0.19</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.44<break/>(0.98 to 2.14)<break/>p: 0.06</td><td align="left" valign="top" rowspan="1" colspan="1">OR: 1.15<break/>(0.77 to 1.73)<break/>p: 0.50</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>EUGOGO, European Group on Graves' Orbitopathy; TED, thyroid eye disease.</p></fn></table-wrap-foot></table-wrap><p>After 2020, by incorporating verbal counselling as a routine portion of care at the TED clinic in Rassoul Akram Hospital, a substantial number of patients who reported smoking during their initial visit disclosed successful smoking cessation during a follow-up phone call (<xref rid="F2" ref-type="fig">figure 2</xref>). Out of the 51 smoker patients contacted, 25 (49.01%) reported successful smoking cessation following verbal counselling. Based on the inclusion criteria, the case selection process yielded two groups: 12 patients who continued smoking (persistent smokers) and 16 patients who successfully quit (quitters). These groups were then compared based on their <italic toggle="yes">baseline</italic> characteristics (<xref rid="T2" ref-type="table">table 2</xref>) and the changes observed during follow-up (<xref rid="T3" ref-type="table">table 3</xref>). The average time between visits was 7.9 months (SD=5.2) for individuals who did not quit smoking and 10.9 months (SD=6.9) for those who quit (p=0.23). Persistent smokers in the study had a higher average age of 50.25 years compared with those who quit smoking, with a mean age of 42.50 years (p=0.07). In this study, no significant differences in clinical manifestations were observed between persistent smokers and successful quitters at the baseline (<xref rid="T2" ref-type="table">table 2</xref>). An analysis comparing previsit and postvisit indices indicated that patients who experienced worsening TED severity during their disease progression were more likely to quit smoking. The mean severity score <italic toggle="yes">change</italic> was &#8722;1.66 (SD=4.43) for persistent smokers and +4.06 (SD=7.04) for quitters (p=0.02). Even when changes in disease severity were categorised qualitatively (categorically) as worsening, stable or improving, the distinction between persistent smokers and those who successfully quit smoking remained statistically significant (<xref rid="T3" ref-type="table">table 3</xref>), both in statistical tests to measure association in <italic toggle="yes">nominal</italic> and <italic toggle="yes">ordinal</italic> categorical variables. This indicates that patients who endured TED severity aggravation throughout their disease progression showed a higher likelihood of smoking cessation. No statistically significant differences were found between the two groups regarding changes in CAS scores or shifts in disease activity classification (<xref rid="T3" ref-type="table">table 3</xref>).</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Flow diagram outlining the steps involved in patient selection and varenicline treatment course. IrTED, Iran Thyroid Eye Disease.</title></caption><graphic position="float" orientation="portrait" xlink:href="bmjophth-10-1-g002.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Comparison of clinical characteristics between successful quitters and persistent smokers</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">Still smoking<break/>(n=12)</th><th valign="bottom" rowspan="1" colspan="1">Quit smoking<break/>(n=16)</th><th valign="bottom" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">52.00 (31.0&#8211;64.0)</td><td align="left" valign="top" rowspan="1" colspan="1">41.00 (26.0&#8211;62.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.07<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male/female)</td><td align="left" valign="top" rowspan="1" colspan="1">9/3</td><td align="left" valign="top" rowspan="1" colspan="1">12/4</td><td align="left" valign="top" rowspan="1" colspan="1">1.00<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking dose (fags/day)<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">15.00 (5.0&#8211;40.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11.00 (3.0&#8211;30.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.58<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TED duration (months)<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">12.00 (2.0&#8211;103.0)</td><td align="left" valign="top" rowspan="1" colspan="1">5.50 (1.0&#8211;110.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.63<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">The interval between the two visits (months)<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">7.00 (3.0&#8211;20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">9.00 (3.0&#8211;31.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.24<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of eye surgery</td><td align="left" valign="top" rowspan="1" colspan="1">2/12</td><td align="left" valign="top" rowspan="1" colspan="1">0/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.17<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History of systemic steroid</td><td align="left" valign="top" rowspan="1" colspan="1">5/12</td><td align="left" valign="top" rowspan="1" colspan="1">9/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.70<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ocular pain<xref rid="T2_FN2" ref-type="table-fn">&#8224;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">2/12</td><td align="left" valign="top" rowspan="1" colspan="1">4/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.67<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tearing</td><td align="left" valign="top" rowspan="1" colspan="1">9/12</td><td align="left" valign="top" rowspan="1" colspan="1">7/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.13<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diplopia<xref rid="T2_FN6" ref-type="table-fn">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">8/12</td><td align="left" valign="top" rowspan="1" colspan="1">6/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.25<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proptosis<xref rid="T2_FN3" ref-type="table-fn">&#8225;</xref> (mm)<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">4.00 (0.0&#8211;10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4.25 (0.0&#8211;10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.45<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Conjunctival redness</td><td align="left" valign="top" rowspan="1" colspan="1">7/12</td><td align="left" valign="top" rowspan="1" colspan="1">10/16</td><td align="left" valign="top" rowspan="1" colspan="1">1.00<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemosis</td><td align="left" valign="top" rowspan="1" colspan="1">2/12</td><td align="left" valign="top" rowspan="1" colspan="1">1/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.56<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clinical activity score (CAS)<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">3.00 (0.0&#8211;4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2.50 (0.0&#8211;5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.69<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Active thyroid eye disease<xref rid="T2_FN4" ref-type="table-fn">&#167;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">8/12</td><td align="left" valign="top" rowspan="1" colspan="1">8/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.45<sup><xref rid="T2_FN5" ref-type="table-fn">&#182;</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NOSPECS severity score<break/>Median (range)</td><td align="left" valign="top" rowspan="1" colspan="1">17.50 (5.0&#8211;40.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11.50 (3.0&#8211;30.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.59<xref rid="T2_FN1" ref-type="table-fn">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1" fn-type="other"><label>*</label><p>Mann-Whitney U test.</p></fn><fn id="T2_FN2" fn-type="other"><label>&#8224;</label><p>Spontaneous or by movement.</p></fn><fn id="T2_FN3" fn-type="other"><label>&#8225;</label><p>Worst eye.</p></fn><fn id="T2_FN4" fn-type="other"><label>&#167;</label><p>CAS score equal to or more than 3.</p></fn><fn id="T2_FN5" fn-type="other"><label>&#182;</label><p>Fisher&#8217;s exact test significance (two-sided).</p></fn><fn id="T2_FN6" fn-type="other"><label>**</label><p>Primary gaze, extreme gaze, or intermittent diplopia.</p></fn><fn fn-type="abbr"><p>NOSPECS, (N) no signs and symptoms, (O) only signs, (S) soft tissue involvement, (P) proptosis, (E) extraocular muscle involvement, (C) corneal involvement and (S) sight loss; TED, thyroid eye disease.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Comparison of clinical manifestation <italic toggle="yes">changes</italic> (worsening or improving, as opposed to remaining stable) in continuous smokers and successful quitters between the second visit and the first (verbal cessation counselling) visit</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th colspan="2" valign="bottom" rowspan="1">Persistent smokers</th><th colspan="2" valign="bottom" rowspan="1">Successful quitters</th><th rowspan="2" colspan="2" valign="bottom">P value</th></tr><tr><th valign="bottom" rowspan="1" colspan="1">Change</th><th valign="bottom" rowspan="1" colspan="1">Worsening</th><th valign="bottom" rowspan="1" colspan="1">Improving</th><th valign="bottom" rowspan="1" colspan="1">Worsening</th><th valign="bottom" rowspan="1" colspan="1">Improving</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Ocular pain</td><td align="left" valign="top" rowspan="1" colspan="1">2/12</td><td align="left" valign="top" rowspan="1" colspan="1">1/12</td><td align="left" valign="top" rowspan="1" colspan="1">2/16</td><td align="left" valign="top" rowspan="1" colspan="1">3/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.72<xref rid="T3_FN1" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.46<xref rid="T3_FN3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Activity class<xref rid="T3_FN2" ref-type="table-fn">&#8224;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0/12</td><td align="left" valign="top" rowspan="1" colspan="1">4/12</td><td align="left" valign="top" rowspan="1" colspan="1">1/16</td><td align="left" valign="top" rowspan="1" colspan="1">4/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.63<xref rid="T3_FN1" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.47<xref rid="T3_FN3" ref-type="table-fn">&#8225;</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NOSPECS score</td><td align="left" valign="top" rowspan="1" colspan="1">2/12</td><td align="left" valign="top" rowspan="1" colspan="1">7/12</td><td align="left" valign="top" rowspan="1" colspan="1">11/16</td><td align="left" valign="top" rowspan="1" colspan="1">4/16</td><td align="left" valign="top" rowspan="1" colspan="1">0.02<xref rid="T3_FN1" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.01<xref rid="T3_FN3" ref-type="table-fn">&#8225;</xref></td></tr></tbody></table><table-wrap-foot><fn id="T3_FN1" fn-type="other"><label>*</label><p>Pearson &#967;&#178; asymptotic significance (as a measure of association for <italic toggle="yes">nominal</italic> categorical variables).</p></fn><fn id="T3_FN2" fn-type="other"><label>&#8224;</label><p>Change in classification from active to inactive or vice versa (CAS &#8805;3 considered active).</p></fn><fn id="T3_FN3" fn-type="other"><label>&#8225;</label><p>Gamma approximate significance (as a measure of association for <italic toggle="yes">ordinal</italic> categorical variables).</p></fn><fn fn-type="abbr"><p>CAS, clinical activity score; NOSPECS, (N) no signs and symptoms, (O) only signs, (S) soft tissue involvement, (P) proptosis, (E) extraocular muscle involvement, (C) corneal involvement and (S) sight loss.</p></fn></table-wrap-foot></table-wrap><p>Among 51 cigarette smokers contacted, 26 reported persistent smoking (<xref rid="F2" ref-type="fig">figure 2</xref>). When offered varenicline, 12/26 smokers agreed to attempt the medication and scheduled a visit. However, only seven attended and started the medication, with three complying with the first month of treatment. Of these, one patient quit smoking after the first month but discontinued varenicline and restarted smoking 1&#8201;month later. Another patient failed to quit smoking after taking varenicline for 60 days and discontinued the drug. Only one patient completed the 3-month regimen, successfully quitting after the first month and sustaining cessation until the last follow-up (18 months). Two patients experienced side effects while taking varenicline: one reported an unpleasant sleep-related event (sleep paralysis), leading to medication discontinuation and another experienced mild constipation.</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Smoking has been unequivocally recognised as the most significant risk factor for the onset and progression of TED. Research has demonstrated that smoking significantly increases the odds of developing TED by 7.7 times (95% CI, 4.3 to 13.7) when compared with healthy individuals who do not smoke.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> Smoking escalates the risk of ophthalmopathy progression post-radioiodine therapy and reduces the effectiveness of orbital radiation and glucocorticoid therapies.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> Furthermore, it is associated with a higher likelihood of requiring surgical intervention for TED.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> In a study on patients with Graves&#8217; disease, smoking was linked to a 1.3-fold increase in TED incidence, and a 2.6-fold and 3.1-fold increase in proptosis and diplopia incidence, respectively.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> The study revealed that former smokers had a considerably lower risk of developing proptosis and diplopia compared with active smokers who had a similar lifetime cigarette consumption. This finding emphasises the benefits of smoking cessation in reducing the risk of these TED-related complications.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref></p><p>In the present study, the observed relationship between smoking status and TED severity or activity, at the cross-section of the first visit to the oculoplastic clinic, did not persist after controlling for gender (<xref rid="T1" ref-type="table">table 1</xref>). In other words, when women and men are analysed separately, the smoking habit is not associated with increased severity or activity at first visit. This highlights that male patients tend to present more advanced and active stages of the disease. A possible explanation may be men&#8217;s reluctance to seek access to health services. Delayed healthcare seeking in men is supported by a growing body of evidence.<xref rid="R30" ref-type="bibr"><sup>30 31</sup></xref></p><p>While TED severity is not significantly different among active smokers, passive smokers and non-smokers at the cross-section of the <italic toggle="yes">initial presentation</italic>, this finding does not challenge the recognised role of smoking in triggering TED onset and progression in longitudinal studies.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref></p><p>Notably, the active smoking rates among Iranian patients with TED in this study were found to be almost double the national average. The study reported rates of 7.24% for women and 36.68% for men, compared with the average national smoking rates of 4.1% for women and 19.9% for men.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> This emphasises the importance of implementing targeted cessation counselling in oculoplastic centres to address the heightened impact of smoking on TED incidence within this population.</p><p>Verbal counselling in the current study included conveying predetermined evidence-based facts<xref rid="R14" ref-type="bibr"><sup>14 34</sup></xref> to the patients regarding how smoking deteriorates TED. A previous study<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> showed that educating patients about the risks of smoking significantly increased the success rate of quitting from 1/23 (4.3%) to 9/34 (26.5%), resulting in a 22.1% difference (95%&#8201;CI: 1.7% to 39.1%). Similarly, another study reported a 42.4% smoking cessation rate.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> In the present study, cessation counselling was regularly provided to all patients during almost every session, which has contributed to a cessation success rate of 25/51 (49.01%). This indicates that integrating verbal counselling into TED care can significantly increase the likelihood that an active smoker will quit or perhaps reduce smoking. In agreement with previous findings, patients whose TED severity was progressively worsening demonstrated a greater likelihood of quitting smoking (<xref rid="T3" ref-type="table">table 3</xref>). Active and severe TED, stable employment and increased family support have been previously identified as significant predictors of smoking cessation success.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref></p><p>One of the primary objectives of the present study was to determine whether varenicline could be beneficial in smoking patients with TED. This question was specifically addressed through the telephone surveillance phase of the study (<xref rid="F2" ref-type="fig">figure 2</xref>). Remarkably, varenicline was only offered to active smokers who failed to quit smoking after receiving verbal counselling. Therefore, it is important to consider that the limited effectiveness of varenicline observed in this study should be carefully attributed to the specific subset of smokers who have failed a previous verbal counselling and are perhaps more heavily dependent on tobacco, or possess lower motivation for cessation.</p><p>This study shows that if a smoking patient with TED is open to quitting, verbal counselling is likely sufficient and varenicline does not seem to offer additional effectiveness. One might argue that among the three patients who complied with varenicline for at least 1&#8201;month, one managed to quit and sustain a long-term smoking abstinence. This may appear as a reasonable 1/3 efficacy, suggesting that varenicline is a beneficial second-line intervention, provided that this is confirmed in future larger studies. Nonetheless, we would like to draw attention to the difference between drug <italic toggle="yes">effectiveness</italic> (in real-world practice) and <italic toggle="yes">efficacy</italic> (in an optimal situation with all presumptions fulfilled; ie, willingness to take the drug, compliance with the correct dosage, withstanding minor side-effects, adherence to the complete treatment period, etc.). The results indicate that among persistent smoker patients who were offered varenicline, only 1/26 achieved a successful cessation, a clear clue of limited <italic toggle="yes">effectiveness</italic>.</p><p>Some limitations of the present study belong to the cross-sectional methodology, with no certainty about the time order between exposure and outcome. While data suggest that smokers with more severe TED are more likely to quit smoking, another, though less conceivable, interpretation would be that those who stop smoking will develop more severe grades of the disease.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref> Another potential source of bias is the subjective definition of smoking cessation. It is possible that patients with more severe grades of TED feel guilty or stigmatised for their poorer outcome and thus tend to hide their continuous smoking behaviour, that is, give a false report of smoking cessation. In the absence of an objective test to confirm smoking cessation, we cannot rule out this possibility. Despite potential false reports from some patients, the substantial percentage of smoking cessation self-reported through verbal counselling (49.01%) implies that this approach is highly effective.</p><p>In conclusion, this study demonstrates that regularly providing patients with TED with evidence-based, quantitative information on the adverse effects of smoking (particularly the increased risk of proptosis, diplopia and treatment failure) can lead to a cessation rate of up to 50%. Patients experiencing progressive TED deterioration are more likely to quit smoking successfully. For those who do not quit smoking after verbal counselling, varenicline has been shown to have minimal effectiveness.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> This study involves human participants and was approved by Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.FMD.REC.1401.535). Participants gave informed consent to participate in the study before taking part.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbarian</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaibakhsh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kashkouli</surname><given-names>MB</given-names></name><etal>et al</etal></person-group><article-title>A Systematic Review on the Role of Antioxidants in Thyroid Eye Disease</article-title><source>J Curr Ophthalmol</source><year>2022</year><volume>34</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.4103/joco.joco_266_21</pub-id><pub-id pub-id-type="pmid">35620378</pub-id><pub-id pub-id-type="pmcid">PMC9128423</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashkouli</surname><given-names>MB</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>N</given-names></name><name name-style="western"><surname>Aghamirsalim</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Measurement Properties of the Persian Translated Version of Graves Orbitopathy Quality of Life Questionnaire: A Validation Study</article-title><source>Ophthalmic Epidemiol</source><year>2017</year><volume>24</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1080/09286586.2016.1255974</pub-id><pub-id pub-id-type="pmid">28001456</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartley</surname><given-names>GB</given-names></name></person-group><article-title>The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota</article-title><source>Trans Am Ophthalmol Soc</source><year>1994</year><volume>92</volume><fpage>477</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">7886878</pub-id><pub-id pub-id-type="pmcid">PMC1298522</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laurberg</surname><given-names>P</given-names></name><name name-style="western"><surname>Berman</surname><given-names>DC</given-names></name><name name-style="western"><surname>B&#252;low Pedersen</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Incidence and clinical presentation of moderate to severe graves&#8217; orbitopathy in a Danish population before and after iodine fortification of salt</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><fpage>2325</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-1275</pub-id><pub-id pub-id-type="pmid">22518849</pub-id><pub-id pub-id-type="pmcid">PMC3387399</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashkouli</surname><given-names>MB</given-names></name></person-group><article-title>Beyond a typical thyroid eye disease</article-title><source>Middle East Afr J Ophthalmol</source><year>2013</year><volume>20</volume><fpage>185</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.4103/0974-9233.114787</pub-id><pub-id pub-id-type="pmid">24014977</pub-id><pub-id pub-id-type="pmcid">PMC3757623</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashkouli</surname><given-names>MB</given-names></name><name name-style="western"><surname>Kaghazkanani</surname><given-names>R</given-names></name><name name-style="western"><surname>Heidari</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Bilateral versus unilateral thyroid eye disease</article-title><source>Indian J Ophthalmol</source><year>2011</year><volume>59</volume><fpage>363</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.4103/0301-4738.83612</pub-id><pub-id pub-id-type="pmid">21836341</pub-id><pub-id pub-id-type="pmcid">PMC3159317</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashkouli</surname><given-names>MB</given-names></name><name name-style="western"><surname>Pakdel</surname><given-names>F</given-names></name><name name-style="western"><surname>Kiavash</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Hyperthyroid vs hypothyroid eye disease: the same severity and activity</article-title><source>Eye (Lond)</source><year>2011</year><volume>25</volume><fpage>1442</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/eye.2011.186</pub-id><pub-id pub-id-type="pmid">21818129</pub-id><pub-id pub-id-type="pmcid">PMC3213650</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perros</surname><given-names>P</given-names></name><name name-style="western"><surname>Crombie</surname><given-names>AL</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>JN</given-names></name><etal>et al</etal></person-group><article-title>Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic</article-title><source>Clin Endocrinol (Oxf)</source><year>1993</year><volume>38</volume><fpage>367</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2265.1993.tb00516.x</pub-id><pub-id pub-id-type="pmid">8319368</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manji</surname><given-names>N</given-names></name><name name-style="western"><surname>Carr-Smith</surname><given-names>JD</given-names></name><name name-style="western"><surname>Boelaert</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>4873</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-1402</pub-id><pub-id pub-id-type="pmid">16968788</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiersinga</surname><given-names>WM</given-names></name></person-group><article-title>Smoking and thyroid</article-title><source>Clin Endocrinol (Oxf)</source><year>2013</year><volume>79</volume><fpage>145</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/cen.12222</pub-id><pub-id pub-id-type="pmid">23581474</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartalena</surname><given-names>L</given-names></name><name name-style="western"><surname>Piantanida</surname><given-names>E</given-names></name></person-group><article-title>Cigarette smoking: number one enemy for Graves ophthalmopathy</article-title><source>Pol Arch Med Wewn</source><year>2016</year><volume>126</volume><fpage>725</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.20452/pamw.3592</pub-id><pub-id pub-id-type="pmid">27872448</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><etal>et al</etal></person-group><article-title>Smoking was associated with poor response to intravenous steroids therapy in Graves&#8217; ophthalmopathy</article-title><source>Br J Ophthalmol</source><year>2015</year><volume>99</volume><fpage>1686</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2014-306463</pub-id><pub-id pub-id-type="pmid">26061160</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartalena</surname><given-names>L</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>D</given-names></name><name name-style="western"><surname>Tanda</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors</article-title><source><italic toggle="yes">Ophthalmic Plast Reconstr Surg</italic></source><year>2023</year><volume>39</volume><fpage>S2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/IOP.0000000000002467</pub-id><pub-id pub-id-type="pmid">38054980</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckstein</surname><given-names>A</given-names></name><name name-style="western"><surname>Quadbeck</surname><given-names>B</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Impact of smoking on the response to treatment of thyroid associated ophthalmopathy</article-title><source>Br J Ophthalmol</source><year>2003</year><volume>87</volume><fpage>773</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/bjo.87.6.773</pub-id><pub-id pub-id-type="pmid">12770979</pub-id><pub-id pub-id-type="pmcid">PMC1771717</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartalena</surname><given-names>L</given-names></name></person-group><article-title>Prevention of Graves&#8217; ophthalmopathy</article-title><source>Best Pract Res Clin Endocrinol Metab</source><year>2012</year><volume>26</volume><fpage>371</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2011.09.004</pub-id><pub-id pub-id-type="pmid">22632372</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeilschifter</surname><given-names>J</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>R</given-names></name></person-group><article-title>Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption</article-title><source>Clin Endocrinol (Oxf)</source><year>1996</year><volume>45</volume><fpage>477</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2265.1996.8220832.x</pub-id><pub-id pub-id-type="pmid">8959089</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>J</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>SP</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>RA</given-names></name><etal>et al</etal></person-group><article-title>Cigarette smoking and thyroid eye disease: a systematic review</article-title><source>Eye (Lond)</source><year>2007</year><volume>21</volume><fpage>1135</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/sj.eye.6702603</pub-id><pub-id pub-id-type="pmid">16980921</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de-Arriba-Palomero</surname><given-names>P</given-names></name><name name-style="western"><surname>Sales-Sanz</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuentemilla</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Effectiveness of oral counselling for smoke cessation in Graves orbitopathy patients</article-title><source>Arch Soc Esp Oftalmol (Engl Ed)</source><year>2019</year><volume>94</volume><fpage>323</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.oftale.2019.03.004</pub-id><pub-id pub-id-type="pmid">31036428</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karadimas</surname><given-names>P</given-names></name><name name-style="western"><surname>Bouzas</surname><given-names>EA</given-names></name><name name-style="western"><surname>Mastorakos</surname><given-names>G</given-names></name></person-group><article-title>Advice against smoking is not effective in patients with Graves&#8217; ophthalmopathy</article-title><source>Acta Med Austriaca</source><year>2003</year><volume>30</volume><fpage>59</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1046/j.1563-2571.2003.03007.x</pub-id><pub-id pub-id-type="pmid">12752091</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nethan</surname><given-names>ST</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>DN</given-names></name><name name-style="western"><surname>Chandan</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Smokeless tobacco cessation interventions: A systematic review</article-title><source>Indian J Med Res</source><year>2018</year><volume>148</volume><fpage>396</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.4103/ijmr.IJMR_1983_17</pub-id><pub-id pub-id-type="pmid">30666002</pub-id><pub-id pub-id-type="pmcid">PMC6362721</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baraona</surname><given-names>LK</given-names></name><name name-style="western"><surname>Lovelace</surname><given-names>D</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>JL</given-names></name><etal>et al</etal></person-group><article-title>Tobacco Harms, Nicotine Pharmacology, and Pharmacologic Tobacco Cessation Interventions for Women</article-title><source>J Midwifery Womens Health</source><year>2017</year><volume>62</volume><fpage>253</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1111/jmwh.12616</pub-id><pub-id pub-id-type="pmid">28556464</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>JM</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>MB</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Varenicline for tobacco dependence: panacea or plight?</article-title><source>Expert Opin Pharmacother</source><year>2011</year><volume>12</volume><fpage>1799</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1517/14656566.2011.587121</pub-id><pub-id pub-id-type="pmid">21644843</pub-id><pub-id pub-id-type="pmcid">PMC3132819</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>JR</given-names></name><name name-style="western"><surname>Rennard</surname><given-names>SI</given-names></name><name name-style="western"><surname>Fingar</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial</article-title><source>Nicotine Tob Res</source><year>2011</year><volume>13</volume><fpage>955</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntr103</pub-id><pub-id pub-id-type="pmid">21652735</pub-id><pub-id pub-id-type="pmcid">PMC3218639</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbarian</surname><given-names>S</given-names></name><name name-style="western"><surname>Sheikhtaheri</surname><given-names>A</given-names></name><name name-style="western"><surname>Khorrami</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Implementation of thyroid eye disease registry in Iran: rationale and research protocol</article-title><source>Orphanet J Rare Dis</source><year>2024</year><volume>19</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/s13023-024-03053-9</pub-id><pub-id pub-id-type="pmid">38321499</pub-id><pub-id pub-id-type="pmcid">PMC10845661</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbarian</surname><given-names>S</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>N</given-names></name><name name-style="western"><surname>Farhangniya</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Iran Thyroid Eye Disease (IrTED) Registry: Patient Characteristics and Clinical Presentation</article-title><source>Semin Ophthalmol</source><year>2025</year><volume>40</volume><fpage>412</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1080/08820538.2025.2463946</pub-id><pub-id pub-id-type="pmid">39924353</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>SC</given-names></name></person-group><article-title>Classification of the eye changes of Graves&#8217; disease</article-title><source>Am J Ophthalmol</source><year>1969</year><volume>68</volume><fpage>646</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0002-9394(69)91246-x</pub-id><pub-id pub-id-type="pmid">5394450</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prummel</surname><given-names>MF</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>WM</given-names></name></person-group><article-title>Smoking and risk of Graves&#8217; disease</article-title><source>JAMA</source><year>1993</year><volume>269</volume><fpage>479</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">8419666</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartalena</surname><given-names>L</given-names></name><name name-style="western"><surname>Marcocci</surname><given-names>C</given-names></name><name name-style="western"><surname>Tanda</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Cigarette smoking and treatment outcomes in Graves ophthalmopathy</article-title><source>Ann Intern Med</source><year>1998</year><volume>129</volume><fpage>632</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-129-8-199810150-00010</pub-id><pub-id pub-id-type="pmid">9786811</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oke</surname><given-names>I</given-names></name><name name-style="western"><surname>Reshef</surname><given-names>ER</given-names></name><name name-style="western"><surname>Elze</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Smoking Is Associated With a Higher Risk of Surgical Intervention for Thyroid Eye Disease in the IRIS Registry</article-title><source>Am J Ophthalmol</source><year>2023</year><volume>249</volume><fpage>174</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2023.01.020</pub-id><pub-id pub-id-type="pmid">36690290</pub-id><pub-id pub-id-type="pmcid">PMC10767645</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galdas</surname><given-names>PM</given-names></name><name name-style="western"><surname>Cheater</surname><given-names>F</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>P</given-names></name></person-group><article-title>Men and health help-seeking behaviour: literature review</article-title><source>J Adv Nurs</source><year>2005</year><volume>49</volume><fpage>616</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2648.2004.03331.x</pub-id><pub-id pub-id-type="pmid">15737222</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdullah</surname><given-names>NN</given-names></name><name name-style="western"><surname>Mohd Arsat</surname><given-names>MH</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>NRA</given-names></name><etal>et al</etal></person-group><article-title>Men Health Seeking Behaviour: A literature review</article-title><source>E-BPJ</source><year>2022</year><volume>7</volume><fpage>247</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.21834/ebpj.v7i20.3484</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winsa</surname><given-names>B</given-names></name><name name-style="western"><surname>Mandahl</surname><given-names>A</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>FA</given-names></name></person-group><article-title>Graves&#8217; disease, endocrine ophthalmopathy and smoking</article-title><source>Acta Endocrinol (Copenh)</source><year>1993</year><volume>128</volume><fpage>156</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1530/acta.0.1280156</pub-id><pub-id pub-id-type="pmid">8451910</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahmohamadi</surname><given-names>E</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>National and Provincial Prevalence of Cigarette Smoking in Iran; A Systematic Analysis of 12 Years of STEPS Experience</article-title><source>Arch Iran Med</source><year>2023</year><volume>26</volume><fpage>472</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.34172/aim.2023.72</pub-id><pub-id pub-id-type="pmid">38310402</pub-id><pub-id pub-id-type="pmcid">PMC10862053</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stan</surname><given-names>MN</given-names></name><name name-style="western"><surname>Bahn</surname><given-names>RS</given-names></name></person-group><article-title>Risk factors for development or deterioration of Graves&#8217; ophthalmopathy</article-title><source>Thyroid</source><year>2010</year><volume>20</volume><fpage>777</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1089/thy.2010.1634</pub-id><pub-id pub-id-type="pmid">20578901</pub-id><pub-id pub-id-type="pmcid">PMC3357079</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schatz</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McGeehan</surname><given-names>BC</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>MG</given-names></name><etal>et al</etal></person-group><article-title>Tobacco counseling in the setting of thyroid eye disease</article-title><source>Arq Bras Oftalmol</source><year>2022</year><volume>85</volume><fpage>13</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.5935/0004-2749.20220003</pub-id><pub-id pub-id-type="pmid">34586224</pub-id><pub-id pub-id-type="pmcid">PMC11826631</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>E</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Lim</surname><given-names>MK</given-names></name><etal>et al</etal></person-group><article-title>Cancer Risk Following Smoking Cessation in Korea</article-title><source><italic toggle="yes">JAMA Netw Open</italic></source><year>2024</year><volume>7</volume><elocation-id>e2354958</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.54958</pub-id><pub-id pub-id-type="pmid">38319658</pub-id><pub-id pub-id-type="pmcid">PMC10848071</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data availability statement</title><p>All data relevant to the study are included in the article or uploaded as supplementary information.</p></sec></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>